摘要
目的 探讨伊伐布雷定联合美托洛尔对心力衰竭患者心率变异性和QT离散度的影响.方法 选择我院收治的慢性心力衰竭患者90例为研究对象,随机分为对照组和观察组,每组45例.在对症治疗的基础上,对照组患者应用美托洛尔进行治疗,而观察组患者在对照组的用药基础上加用伊伐布雷定治疗,连续治疗12周后对两组患者的心率变异性相关参数和QT离散度进行检测和比较.结果 治疗前,两组患者的各项参数指标之间差异无统计学意义(P>0.05);治疗后,两组患者的QT离散度明显缩短,而心率变异性相关参数SDNN、rMSSD、SDANN、RNN50均明显升高,与同组治疗前之间差异有统计学意义(P<0.05),且两组患者之间差异也有统计学意义(P<0.05);两组患者不良反应发生率之间差异无统计学意义(P>0.05).结论 联合应用伊伐布雷定和美托洛尔治疗慢性心力衰竭患者,可以明显缩短QT离散度,升高心率变异性.
Objective To explore the effect of ivabradine combined with metoprolol on heart rate variability(HRV) and QT dispersion(QTd) in patients with heart failure. Methods 90 patients with chronic heart failure admitted to our hospital were selected as research subjects and randomly divided into the control group and the observation group, with 45 patients in each group. On the basis of symptomatic treatment, the patients of the control group were treated with metoprolol, while the patients of the observation group were treated with ivabradine based on metoprolol administered to the control group. After twelve weeks of continuous treatment, the HRV related parameters and QTd of the two groups were detected and compared. Results Before treatment, there was no statistically significant difference between the patients of the two groups in all parameters and indicators(P > 0.05). After treatment, QTd of the two groups of patients was significantly shortened, while the HRV related parameters such as SDNN, rMSSD, SDANN and RNN50 all significantly increased, with statistically significant difference from those before treatment in each group(P < 0.05), and the difference between the two groups of patients was also statistically significant(P < 0.05). There was no statistically significant difference in the incidence of adverse reactions(ADRs) between the two groups(P > 0.05). Conclusion Combined application of ivabradine and metoprolol in the treatment of the patients with chronic heart failure can significantly shorten QTd and increase HRV.
作者
薛丹
XUE Dan(ECG Room,Jiangyin People’s Hospital,Jiangsu,Jiangyin 214400,China)
出处
《中国医药科学》
2020年第14期85-87,共3页
China Medicine And Pharmacy